Please login to the form below

macular oedema

This page shows the latest macular oedema news and features for those working in and with pharma, biotech and healthcare.

The lead molecule of this partnership is THR-149, a novel plasma kallikrein inhibitor, for the treatment of diabetic macular oedema.

After Lucentis setback, Novartis trumpets data on follow-up drug

The experimental therapy – called brolucizumab (RTH258) – showed its was superior to a Bayer and Regeneron’s Eylea (aflibercept) in tackling a key disease activity marker in age-related macular degeneration (AMD), ... In addition to nAMD, Novartis
Regeneron and Bayer drop AMD combination

Abandon plans after disappointing phase II trial results. Regeneron has abandoned a combination therapy for age-related macular degeneration after disappointing phase II data, handing an advantage to would-be rival ... advance the duo into phase III in
Lucentis claims speedy FDA review for myopia complication

in the EU myopic CNV market, adding to their rivalry in other indications such as wet age-related macular degeneration and diabetic macular oedema.
NICE backs Bayer’s Eylea as first-line BRVO treatment

This treatment continues to achieve positive results in real-life clinical practice, similar to that demonstrated in clinical trials, and we hope that this will continue for patients with macular oedema ... its rivals in macular oedema Roche's Avastin
NICE gives Bayer's Elyea a provisional 'no' for first-line use

The provisional guidance in NICE's Appraisal Consultation Document only recommends Eylea in visual impairment in adults caused by macular oedema if laser photocoagulation has not been beneficial or is not ... NICE has previously recommended Eylea to

More from news
Approximately 8 fully matching, plus 36 partially matching documents found.

Diagnosed Anywhere

The system creates an immediate, reliable assessment for diabetic retinopathy, including macular oedema, during a routine office visit in a primary care setting.
Medius Deal Watch table for February 2015

Majority acquisition. 380. Pfenex/ Hospira. PF582 - LUCENTIS biosimilar candidate - wet age-related macular degeneration, diabetic macular oedema.
Allergan and taking a specialised approach

spasticity associated with stroke and for the ophthalmology treatment Ozurdex in diabetic macular oedema.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

RWE Blog 1: Real-world challenges and real-world data

Greater improvement of key clinical outcomes in patients with diabetic macular oedema from a real-world study of a fluocinolone intravitreal implant, compared with the results of the FAME (Fluocinolone Acetonide ... in Diabetic Macular Edema) RCTs.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Add my company

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Emotion-driven clinical trial marketing: A missed opportunity?: Whether we’re conscious of it or not, our emotions play a huge role in day-to-day decision making. Psychological scientists have long explored emotional influences on decision making. Experts like Herbert...
Virtual Hackathon on Healthcare Innovation: a Customer Story: How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA: Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...